BIOMAT Database Logo BIOMAT Database Logo

Trazodone in late life depressive states: a double-blind multicenter study versus amitriptyline and mianserin. 1988

A C Altamura, and M C Mauri, and F Colacurcio, and P L Scapicchio, and C Hadjchristos, and G Carucci, and M Minervini, and R Montanini, and M Perini, and N Rudas
Department of Clinical Psychiatry, University of Milan Policlinico, Italy.

Seventy five elderly depressed in-patients, ages ranging from 60 to 83 years, diagnosed as Major Depression according to DSM III were treated, under double-blind conditions, with 75 mg Amitriptyline (AMI) (26 patients), 60 mg Mianserin (MIA) (24 patients) or 150 mg Trazodone (TRZ) (25 patients) p.o. for 5 weeks. There were no differences in the clinical outcome between the three groups of patients at the end of the trial, with a significant amelioration (P less than 0.01) at the Hamilton Rating Scale for Depression and Geriatric Depression Scale. TRZ showed a significantly lower incidence of side effects compared to MIA and AMI. Atypical antidepressants, including TRZ, seem more suitable for treating elderly depression than the first generation antidepressants on the basis of risk/benefit ratio considerations.

UI MeSH Term Description Entries
D008297 Male Males
D008803 Mianserin A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors. Lerivon,Mianserin Hydrochloride,Mianserin Monohydrochloride,Org GB 94,Tolvon,Hydrochloride, Mianserin,Monohydrochloride, Mianserin
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

A C Altamura, and M C Mauri, and F Colacurcio, and P L Scapicchio, and C Hadjchristos, and G Carucci, and M Minervini, and R Montanini, and M Perini, and N Rudas
Mianserin versus amitriptyline for depression: a double-blind 6-week trial.
January 1984, Neuropsychobiology,
A C Altamura, and M C Mauri, and F Colacurcio, and P L Scapicchio, and C Hadjchristos, and G Carucci, and M Minervini, and R Montanini, and M Perini, and N Rudas
Mianserin versus amitriptyline. A double-blind-trial evaluated by the AMP system.
January 1976, International pharmacopsychiatry,
A C Altamura, and M C Mauri, and F Colacurcio, and P L Scapicchio, and C Hadjchristos, and G Carucci, and M Minervini, and R Montanini, and M Perini, and N Rudas
Clinical response to amitriptyline and chlordiazepoxide-amitriptyline (Limbitrol) in anxiety-depressive states. A double-blind study.
January 1973, Psychosomatics,
A C Altamura, and M C Mauri, and F Colacurcio, and P L Scapicchio, and C Hadjchristos, and G Carucci, and M Minervini, and R Montanini, and M Perini, and N Rudas
Paroxetine in the treatment of depression. A double-blind multicenter study versus mianserin.
June 1988, Acta psychiatrica Scandinavica,
A C Altamura, and M C Mauri, and F Colacurcio, and P L Scapicchio, and C Hadjchristos, and G Carucci, and M Minervini, and R Montanini, and M Perini, and N Rudas
A double-blind comparative trial with mianserin and amitriptyline in outpatients with major depressive disorders.
January 1983, British journal of clinical pharmacology,
A C Altamura, and M C Mauri, and F Colacurcio, and P L Scapicchio, and C Hadjchristos, and G Carucci, and M Minervini, and R Montanini, and M Perini, and N Rudas
Trazodone and amitriptyline in treatment of depressed inpatients. A double-blind study.
September 1981, Pharmacopsychiatria,
A C Altamura, and M C Mauri, and F Colacurcio, and P L Scapicchio, and C Hadjchristos, and G Carucci, and M Minervini, and R Montanini, and M Perini, and N Rudas
Dibenzepin and amitriptyline in depressive states: comparative double-blind trial.
March 1976, The New Zealand medical journal,
A C Altamura, and M C Mauri, and F Colacurcio, and P L Scapicchio, and C Hadjchristos, and G Carucci, and M Minervini, and R Montanini, and M Perini, and N Rudas
Treatment of severe depressive illness: a double-blind comparison of mianserin and long-acting amitriptyline.
June 1982, The British journal of clinical practice,
A C Altamura, and M C Mauri, and F Colacurcio, and P L Scapicchio, and C Hadjchristos, and G Carucci, and M Minervini, and R Montanini, and M Perini, and N Rudas
A double-blind clinical trial of mianserin versus amitriptyline: differentiation by adverse symptomatology.
January 1983, Pharmacotherapy,
A C Altamura, and M C Mauri, and F Colacurcio, and P L Scapicchio, and C Hadjchristos, and G Carucci, and M Minervini, and R Montanini, and M Perini, and N Rudas
[Effectiveness and tolerance of amitriptyline oxide in chronic tension headache--a multicenter double-blind study versus amitriptyline versus placebo].
February 1993, Der Nervenarzt,
Copied contents to your clipboard!